Glucocorticoid response elements and 11β-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression

Cardiovascular Research

Volumn 81, Issue 1, 2009, Pages 140-147

  Liu, Yong ^a   Mladinov, Domagoj ^a   Pietrusz, Jennifer L ^a   Usa, Kristie ^a   Liang, Mingyu ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Endothelium; Gene expression; Hypertension; Promoter; RNA interference

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DNA RESPONSIVE ELEMENT; ENDOTHELIUM CELL; ENZYME REGULATION; EXPERIMENTAL RAT; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION SITE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; BASE SEQUENCE; CARBENOXOLONE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; KIDNEY MEDULLA; MALE; MOLECULAR SEQUENCE DATA; NITRIC OXIDE SYNTHASE TYPE III; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY;

EID: 57749171127     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn231     Document Type: Article

References (41)

1. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003;138:980-991.
2. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 1999;96:13357-13362.
3. Liang M, Knox FG. Production and functional roles of nitric oxide in the proximal tubule. Am J Physiol Regul Integr Comp Physiol 2000;278:R1117-R1124.
4. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-479.
5. Schafer SC, Wallerath T, Closs EI, Schmidt C, Schwarz PM, Forstermann U et al. Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles. Am J Physiol Heart Circ Physiol 2005;288:H436-H444.
6. Rogers KM, Bonar CA, Estrella JL, Yang S. Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol Heart Circ Physiol 2002;283:H1922-H1928.
7. Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004;1680:114-128.
8. Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 2004;10:2807-2816.
9. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005;186:251-271.
10. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003;88:2384-2392.
11. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-585.
12. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;2:821-824.
13. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-866.
14. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M et al. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 2000;36:187-194.
15. Bocchi B, Kenouch S, Lamarre-Cliche M, Muffat-Joly M, Capron MH, Fiet J et al. Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension 2004;43:803-808.
16. Franks PW, Knowler WC, Nair S, Koska J, Lee YH, Lindsay RS et al. Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension 2004;44:681-688.
17. Liang M, Yuan B, Rute E, Greene AS, Olivier M, Cowley AW Jr. Insights into Dahl salt-sensitive hypertension revealed by temporal patterns of renal medullary gene expression. Physiol Genomics 2003;12:229-237.
18. Watson B Jr, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996;28:478-482.
19. Brand E, Kato N, Chatelain N, Krozowski ZS, Jeunemaitre X, Corvol P et al. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. J Hypertens 1998;16:1627-1633.
20. Melander O, Orho-Melander M, Bengtsson K, Lindblad U, Rastam L, Groop L et al. Association between a variant in the 11 betahydroxysteroid dehydrogenase type 2 gene and primary hypertension. J Hum Hypertens 2000;14:819-823.
21. White PC, Agarwal AK, Li A, Nikkila H, Pratt JH, Caulfield M et al. Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people. Clin Endocrinol (Oxf) 2001;55:249-252.
22. Taylor NE, Glocka P, Liang M, Cowley AW Jr. NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 2006;47:692-698.
23. Usa K, Singh RJ, Netzel BC, Liu Y, Raff H, Liang M. Renal interstitial corticosterone and 11-dehydrocorticosterone in conscious rats. Am J Physiol Renal Physiol 2007;293:F186-F192.
24. Liang M, Pietrusz JL. Thiol-related genes in diabetic complications: a novel protective role for endogenous thioredoxin 2. Arterioscler Thromb Vasc Biol 2007;27:77-83.
25. Tian Z, Greene AS, Usa K, Matus IR, Bauwens J, Pietrusz JL et al. Renal regional proteomes in young Dahl salt-sensitive rats. Hypertension 2008;51:899-904.
26. Liu Y, Park F, Pietrusz JL, Jia G, Singh RJ, Netzel BC et al. Suppression of 11fbetag-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis. Physiol Genomics 2008;32:343-351.
27. Knoll K, Pietrusz JL, Liang M. Tissue-specific transcriptome responses in rats with early streptozotocin-induced diabetes. Physiol Genomics 2005;21:222-229.
28. Liang M, Knox FG. Nitric oxide activates PKCa and inhibits Na+-K+-ATPase in opossum kidney cells. Am J Physiol Renal Physiol 1999;277:F859- F865.
29. Liang M, Croatt TJ, Nath KA. Mechanisms underlying the induction of heme oxygenase-1 by nitric oxide in renal tubular epithelial cells. Am J Physiol Renal Physiol 2000;279:F728-F735.
30. Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008;18:404-411.
31. Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998;31:459-462.
32. Gooch KJ, Frangos JA. Flow- and bradykinin-induced nitric oxide production by endothelial cells is independent of membrane potential. Am J Physiol 1996;270:C546-C551.
33. Gorges R, Knappe G, Gerl H, Ventz M, Stahl F. Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J Endocrinol Invest 1999;22:241-249.
34. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995;270:15320- 15326.
35. Karantzoulis-Fegaras F, Antoniou H, Lai SL, Kulkarni G, D'Abreo C, Wong GK et al. Characterization of the human endothelial nitric-oxide synthase promoter. J Biol Chem 1999;274:3076-3093.
36. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS et al. Localization of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988;2:986- 989.
37. Souness GW, Brem AS, Morris DJ. 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002;67:195-201.
38. Hadoke PW, Christy C, Kotelevtsev YV, Williams BC, Kenyon CJ, Seckl JR et al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 2001;104:2832-2837.
39. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 2003;42:580-587.
40. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006;47:671-679.
41. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37:801-805.